Diabetes Drugs and Mental Health
Medications such as semaglutide, commonly prescribed for diabetes and obesity, may help prevent the worsening of anxiety and depression, according to recent research. Type 2 diabetes affects millions globally, and studies indicate that individuals with this condition are approximately twice as likely to experience anxiety and depression compared to the general population.
GLP-1 receptor agonists, including semaglutide, are widely used to manage diabetes and obesity. While these drugs have demonstrated benefits beyond weight loss and improved blood sugar control, their impact on mental health has remained uncertain.
Study Overview and Methodology
An international team of researchers analyzed Swedish health records of nearly 95,000 individuals diagnosed with depression or anxiety who were also prescribed various diabetes medications between 2009 and 2022. The study compared periods during which patients were taking GLP-1 receptor agonists or other diabetes drugs with periods when they were not on these medications.
Worsening mental health was evaluated using data on psychiatric hospital admissions, sick leave due to mental health reasons, hospitalizations related to self-harm, and suicide deaths. Additionally, the research, published in The Lancet Psychiatry, examined new diagnoses of anxiety and depression.
Key Findings
The authors reported that semaglutide, the active ingredient in Ozempic (for diabetes) and Wegovy (for weight loss), as well as liraglutide (Saxenda), were linked to a decreased risk of worsening mental illness among individuals with anxiety and depression.
Specifically, semaglutide was associated with a 42% lower risk of mental health deterioration, while liraglutide corresponded to an 18% lower risk. Other GLP-1 receptor agonists, such as exenatide and dulaglutide, did not demonstrate similar benefits.
Further analysis revealed that semaglutide was linked to a 44% reduced risk of worsening depression, a 38% lower risk of worsening anxiety, and a 47% decreased risk of worsening substance use disorder.
Authors' Conclusions and Expert Commentary
“For anxiety and depression that co-occur with diabetes and obesity, semaglutide and, to a lesser extent, liraglutide might be useful dually effective therapeutic options,” the authors concluded.
Dr. Markku Lähteenvuo, research director at the University of Eastern Finland, suggested possible mechanisms behind these findings:
“It is possible that, in addition to factors such as reduced alcohol consumption, weight loss-related improvements in body image, or relief associated with better glycaemic control in diabetes, there may also be direct neurobiological mechanisms involved, for example, through changes in the functioning of the brain’s reward system.”
However, experts have urged caution in interpreting these results. Professor David Nutt, head of the neuropsychopharmacology unit at Imperial College London and chair of the independent scientific committee Drug Science, remarked:
“It is well established that better mental health tends to follow from better physical health and since the 1880s we have known that , although I think it’s unlikely that using GLP-1R agonists alone as treatments for depression or anxiety will work.”
Professor Eduard Vieta, professor of psychiatry at the University of Barcelona and editor-in-chief of the European College of Neuropsychopharmacology journal, added:
“From a clinical perspective, these findings are reassuring regarding the psychiatric safety of GLP-1 receptor agonists and suggest a potential role not only in preventing worsening but also, possibly, in improving mental health outcomes. However, they should not yet be interpreted as evidence of a direct therapeutic effect on depression or anxiety.”
Related Research on Pregnancy Risks
In related findings, a study published recently found that women who took semaglutide for diabetes before knowing they were pregnant had an 84% higher relative risk of preterm birth compared to those who did not use GLP-1 medications. The risk was 70% higher among women taking liraglutide.
Researchers examined Danish health registries covering nearly 500,000 women, of whom 529 had been prescribed liraglutide or semaglutide at the time of conception.
The study indicated that inadvertent exposure to GLP-1 receptor agonists during early pregnancy was associated with an increased risk of babies being born before 37 weeks gestation when the drugs were used for diabetes treatment. This association was not observed among women taking these medications for weight loss.
Specifically, semaglutide was linked to an approximately 11% higher absolute risk of preterm birth, while liraglutide showed a 9% increased risk.
